

GENOMICS | DIAGNOSTIC TESTS | GENETICS | R&D

Genomic Vision launches its IPO on the regulated market of Euronext in Paris

- **Indicative price range: €13.5 to €16.5 per share**
- **Amount raised: approx €20.0m, potentially increased up to a maximum of €26.4m (based on the midpoint of the indicative price range)**
- **Subscription undertakings: €3.0m**
- **Closing of the Open Price Offering (Offre à Prix Ouvert): March 31st, 2014**
- **Closing of the Global Placement: April 1st, 2014 (at noon)**

Bagneux (France) - Genomic Vision (the « Company »), a biotechnology company that specializes in the development of diagnostic tests for genetic diseases and cancers using the DNA molecular combing process, today announces the launch of its initial public offering in anticipation of the listing of its shares on the regulated market of Euronext in Paris (Compartment C).

Following the registration of its *Document de Base* under reference number I. 14-005 on March 3rd, 2014, the *Autorité des marchés financiers* (AMF, the French financial markets authority) granted visa number 14-087 dated March 19th, 2014 to the prospectus relative to the initial public offering of Genomic Vision.

Use of proceeds

The proceeds from the IPO are intended to provide the Company with additional resources to finance its operations, more specifically, regardless of the net proceeds the Offering:

- to fund the development of sales in Europe, in particular costs connected to the establishment of a technical/sales team and to make molecular combing platforms available for clients;
- to finance ongoing projects aimed at improving the technological platform (industrialisation of the new high-throughput scanner, image analysis algorithms, etc.) with a view to reducing the time required for analysis and reviewing the results; and
- to support the R&D effort required to develop new products.

Genomic Vision: a French company with unique global technology capable of detecting large genome rearrangements

- **Molecular combing: technology providing a panoramic view of the DNA**
- **An oncogenetic test market worth billions and growing fast**
- **A portfolio of tests at a late stage of development, including one test already marketed**
- **A strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests**

Molecular combing: technology providing a panoramic view of the DNA

The DNA molecular combing technology used by Genomic Vision significantly improves the detection of structural variations at the origin of numerous genetic diseases and hereditary forms of cancer. This unique technology stretches out DNA fibers on glass slides, as if “combed”, and makes it possible to identify genetic anomalies by locating genes or specific sequences in a patient’s genome using genetic markers. This exploration of regions of the genome at high resolution via a simple analysis allows the direct visualization of genetic anomalies that are undetectable by other technologies.

An oncogenetic test market worth billions and growing fast

Genomic Vision targets a number of indications, including breast cancer, the most common cancer in women with around a million new cases diagnosed every year worldwide. Between 5 and 10% of breast cancers are hereditary, and a woman who carries the genetic mutations that cause a predisposition to this type of cancer runs a very high risk of developing this illness. However, this risk can be substantially reduced through early detection and preventative measures¹. In France, the number of oncogenetic consultations tripled between 2003, when the first cancer plan was initiated, and 2011. In the United States, the genetic test market was estimated to be worth 5.9 billion dollars² in 2011, a figure expected to increase to between 15 and 25 billion dollars by 2021 (i.e. average annual growth of between 10 and 15%), including 2 billion dollars for breast cancer alone¹.

A portfolio of tests at a late stage of development, including one test already marketed

Genomic Vision has proved the efficiency of “molecular combing” in detecting facio-scapulo-humeral dystrophy (FSHD), the 2nd most prevalent myopathy. The test for this rare genetic neuromuscular disease, which is very difficult to detect, has been marketed since 2013 in France and in the United States thanks to the Company’s strategic partner Quest Diagnostics. Four other tests are being developed by Genomic Vision, and in particular tests targeting breast cancer and cancer of the colon that should begin to be marketed in 2015.

¹ Source: Myriad Genetics

² Source: Market Trends in Genetic Testing, Booz Allen Hamilton

A strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests

Genomic Vision has signed a licensing and collaboration agreement with Quest Diagnostics, the US leader in diagnostic laboratory tests, in order to jointly finance the development of its tests and ensure their marketing on the world's largest diagnosis market. To date, four Genomic Vision tests have been selected by Quest with a view to marketing them through its network of 2,100 laboratories. Quest Diagnostics has a 21.32% stake in Genomic Vision, thus reflecting its strategic interest in this innovative technology.

Terms of the offering

Structure of the offering

The offering of the new shares will take the form of a global offering (the "**Offering**") consisting of the following:

- A public offering in France in the form of an open price offering (*Offre à Prix Ouvert*) aimed primarily at retail investors (the "OPO"); and
- A global placement aimed primarily at institutional investors in France and in certain countries, except notably the United States of America (the "Global Placement").

Indicative price range

€13.5 to €16.5 per share³

Initial size of the Offering

1,333,333 new shares to be issued, i.e. approximately €20m (based on the midpoint of the indicative price range) taking the form of a capital increase.

Increase option

Up to 199,999 new shares, i.e. approximately €3.0m (based on the midpoint of the indicative price range).

Over allotment option

Up to 229,999 new shares, i.e. approximately €3.0m (based on the midpoint of the indicative price range). The over allotment option may be exercised in one installment at any time, in whole or in part, until April 30th, 2014.

Shareholders' subscription undertakings

In the context of the initial public offering, Quest Diagnostics Ventures LLC and Vesalius Biocapital Holdings SA, historical shareholders of the Company with respectively 21.32% and 56.35% of the share capital, have committed to participate to the capital increase for an amount of respectively €1.0m and €2.0m.

³ The offering price could also be set outside of this indicative price range. In the event that the upper limit of the above-mentioned indicative price range is increased or the offering price is set above the indicative price range (either the initial price range or a revised range), the end of the subscription period in the OPO will be set, such that there will be at least 2 trading days between the date of the announcement of the new price range and the new closing date of the subscription period (inclusive). Orders given in the context of the OPO prior to the publication of any press release announcing a new price range will be maintained, unless and until the purchasers expressly revoke their orders prior to the last day of the new OPO subscription period. The offering price may freely be fixed below the indicative price range and the indicative price range may be freely modified downward (barring material impacts on other aspects of the Global Offering)

Company's and shareholders' lock-up commitments

Company: 180 days

Main shareholders: decreasing gradually over 360 days⁴

Main managers: 360 days

Indicative timetable of the offering

March 19th, 2014	<ul style="list-style-type: none">▪ Approval of the AMF on the Prospectus
March 20th, 2014	<ul style="list-style-type: none">▪ Publication of the press release announcing the Offering▪ Opening of the OPO and Global Placement
March 31st, 2014	<ul style="list-style-type: none">▪ Closing of the OPO at 5 pm (CET) for subscriptions made in person and at 8 pm (CET) for online subscriptions
April 1st, 2014	<ul style="list-style-type: none">▪ Closing of the Global Placement at noon (CET)▪ Setting off of the Offering Price and possible exercise of the Increase Option▪ Publication of the press release announcing the results of the Offering▪ Signing of the Underwriting Agreement▪ Beginning of the stabilization period, as the case may be
April 2nd, 2014	<ul style="list-style-type: none">▪ Beginning of trading for the shares of the Company on the regulated market of Euronext Paris in the form of promises of shares
April 4th, 2014	<ul style="list-style-type: none">▪ Settlement-delivery of the OPO and the Global Placement
April 7th, 2014	<ul style="list-style-type: none">▪ Start of trading for the Company's shares on the regulated market of Euronext Paris
April 30th, 2014	<ul style="list-style-type: none">▪ Deadline for the exercise of the Overallotment Option▪ End of the stabilisation period, as the case may be

Subscription conditions

Those persons wishing to take part in the OPO must submit their orders through an authorised financial intermediary in France, by no later than March 31st, 2014 at 5 pm (CET) for subscriptions over the counter and 8 pm (CET) for online subscriptions. In order to be taken into account, orders issued as part of the Global Placement must be received by one of the Joint Lead Managers and Joint Bookrunners by no later than April 1st, 2014 at noon (CET).

Identification codes for Genomic Vision shares

- **Company name** : Genomic Vision
- **ISIN** : FR0011799907
- **Symbol** : GV
- **Compartment** : Compartment C
- **Sector** : 4573 - Biotechnology (ICB classification)

⁴ From the date of this Prospectus until (i) 180 calendar days for 100% of their shares, (ii) 270 days for 75% of their shares and (iii) 360 days for 25% of their shares following the settlement/delivery date, subject to certain customary exceptions.

Financial intermediaries



Joint Lead Managers and Joint Bookrunners



Company Advisor



Availability of the prospectus – Copies of the prospectus, which received a visa from the AMF on March 19th, 2014 under the number 14-087, composed of the *Document de Base* filed with the AMF on March 3rd, 2014 under the number I. 14-005 and the *Note d'Opération* (including a summary of the prospectus), may be obtained free of charge at Genomic Vision's headquarters, Green Square - Bâtiment E, 80-84 rue des Meuniers, 92220 Bagneux, from the internet websites of Genomic Vision (www.genomicvision.com) and the AMF (www.amf-france.org).

Risk factors – Genomic Vision draws the public's attention to chapter 4, "Risk factors", of the *Document de Base* registered with the AMF, and to chapter 2 "Risk factors related to the Offering" of the *Note d'Opération*.



ABOUT GENOMIC VISION

A spinoff of the Institut Pasteur, Genomic Vision is a biotechnology company specialized in developing diagnostic tests for genetic diseases and cancers. Using "molecular combing", an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

ABOUT MOLECULAR COMBING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed", and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient's genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

Pour en savoir plus: <http://www.genomicvision.com>

CONTACT

Genomic Vision

Aaron Bensimon
Co-founder, President & CEO
Tel.: +33 1 49 08 07 50
investors@genomicvision.com

NewCap.

Investor Relations & Financial
Communications
Dušan Orešanský / Emmanuel Huynh
Tel.: +33 1 44 71 94 92
gv@newcap.fr

DISCLAIMER

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

In particular:

This press release does not constitute an offer to sell or any solicitation to purchase or subscribe for securities in the United States. The shares, or any other securities of GENOMIC VISION, may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended, or exempt from registration. The shares of GENOMIC VISION have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and GENOMIC VISION does not intend to make any public offer of its shares in the United States.

This press release is solely an advertisement and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, in particular, by Directive 2010/73/EC of the European Parliament and the Council of November 24th, 2010 and as implemented in each member State of the European Economic Area (the "Prospectus Directive"). With respect to the member States of the European Economic Area which have transposed the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to in this press release requiring a publication by GENOMIC VISION of a prospectus in any member State, other than France. As a result, the shares of GENOMIC VISION may not be offered or will not be offered in any member State other than France, except, pursuant to the exemptions described in article 3(2) of the Prospectus Directive, if they have been implemented by the relevant member State or in any other circumstances not requiring GENOMIC VISION to publish a prospectus as provided under article 3(2) of the Prospectus Directive and/or regulations applicable in such member State.

This press release is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The prospectus registered with the Autorité des Marchés Financiers contains forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in the prospectus, and to the development of economic conditions, the financial markets and the markets in which GENOMIC VISION operates.

Société Générale, acting as stabilising agent, or any institution acting on its behalf may, during a period of 30 days following the date on which the Offering Price is determined, i.e., according to the indicative timetable, from 1 April to 30 April 2014, effect transactions with a view to maintaining the market price of the GENOMIC VISION shares in a manner consistent with applicable laws and regulations and, in

particular, EU Commission regulation number 2273/03 of 22 December 2003. These activities are intended to support the market price of the GENOMIC VISION shares and may affect the share price.